Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v2.4.0.8
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2014
Fair Value Measurements Tables  
Financial instruments carried at fair value on a recurring
 Description   September 30, 2014    

Quoted Prices in Active Markets

(Level 1)

   

Significant Other Observable Inputs

(Level 2)

   

Unobservable Inputs

(Level 3)

 
Assets:                        
Cash and cash equivalents   $ 3,006     $ 3,006     $ -     $ -  
Marketable securities     5,543       -       5,543       -  
Total assets   $ 8,549     $ 3,006     $ 5,543     $ -  
                                 
Liabilities:                                
Warrants potentially settleable in cash   $ 7,242     $ -     $ -     $ 7,242  
Total liabilities   $ 7,242     $ -     $ -     $ 7,242  
                       
Description   December 31, 2013    

Quoted Prices in Active Markets

(Level 1)

   

Significant Other Observable Inputs

(Level 2)

   

Unobservable Inputs

(Level 3)

 
Assets:                                
Cash and cash equivalents   $ 1,034     $ 1,034     $ -     $ -  
Total assets   $ 1,034     $ 1,034     $ -     $ -  
                                 
Liabilities:                                
Derivative liability   $ 23     $ -     $ -     $ 23  
Total liabilities   $ 23     $ -     $ -     $ 23  
Level 3 financial assets and liabilities
    Fair Value Measurements Using Significant Unobservable Inputs  
    (Level 3)  
Balance, January 1, 2014   $ 23  
Change in fair value of Teva option     (23 )
Estimated fair value of warrants assumed in merger on January 2, 2014     10,475  
Estimated fair value of warrants issued in January common stock sale     3,696  
Change in fair value of warrants for the period ended September 30, 2014     (6,929 )
Balance at September 30, 2014   $ 7,242